Search Results - "Reshetnyak, T"

PO.3.70 Case report of a systemic lupus erythematosus patient with an ulcerative necrotic vasculitis: features of therapeutic approaches by Shumilova, A, Naryshkin, E, Stolyarevich, E, Reshetnyak, T

“…BackgroundSystemic lupus erythematosus (SLE) is a heterogeneous chronic rheumatic autoimmune disease with a range of clinical manifestations, characterized by…”
Get full text

PO.2.42 The value of IGA-ACL and IGA-AB2-GP1 in clinical and laboratory manifestations of systemic lupus erythematosus by Cheldieva, F, Shumilova, A, Reshetnyak, T, Cherkasova, M, Lila, A

“…The study was performed at the V.A. Nasonova Research Institute of Rheumatology within the framework of the fundamental topic FURS-2022–003The immunological…”
Get full text

PO.2.43 The activity and damage index in systemic lupus erythematosus depending on antiphospholipid antibodies by Shumilova, A, Cheldieva, F, Reshetnyak, T, Cherkasova, M, Lila, A

“…The study was performed at the V.A. Nasonova Research Institute of Rheumatology within the framework of the fundamental topic FURS-2022–003BackgroundSystemic…”
Get full text

The first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus by Aseeva, E. A., Pokrovsky, N. S., Soloviev, S. K., Nikolaeva, E. V., Nikishina, N. Yu, Abdullin, E. T., Reshetnyak, T.  M., Zotkin, E. G., Lila, A. M.

“…Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various…”
Get full text

Erratum to: Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus by Reshetnyak, T. M., Cheldieva, F. A., Cherkasova, M. V., Glukhova, S. I., Lila, A. M., Nasonov, E. L.

“…An Erratum to this paper has been published: https://doi.org/10.1134/S160767292305006X…”
Get full text

Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus by Reshetnyak, T. M., Cheldieva, F. A., Cherkasova, M. V., Glukhova, S. I., Lila, A. M., Nasonov, E. L.

“…The role of antiphospholipid antibodies (aPL), which are not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus…”
Get full text

Erratum to: Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus by Cheldieva, F. A., Reshetnyak, T. M., Shumilova, A. A., Nurbaeva, K. S., Cherkasova, M. V., Lila, A. M., Nasonov, E. L.

“…An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050046…”
Get full text

Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus by Cheldieva, F. A., Reshetnyak, T. M., Shumilova, A. A., Nurbaeva, K. S., Cherkasova, M. V., Lila, A. M., Nasonov, E. L.

“…The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid…”
Get full text

Contraception for antiphospholipid syndrome and systemic lupus erythematosus (according to the recommendations of the European Alliance of Associations for Rheumatology/American College of Rheumatology, EULAR/ACR) by Reshetnyak, T. M., Kertchelaeva, S. B., Kosheleva, N. M.

“…Maintaining and strengthening the health of the population is one of the primary functions of society. Inadequate understanding of the importance of…”
Get full text

Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range by Seredavkina, N V, Reshetnyak, T M, Satybaldyeva, M A, Kashnikova, L N, Temnikova, T A, Nasonov, E L

“…The aim of the study was to evaluate the anti - Xa - activity (aXa) of selective and non - selective factor Xa inhibitors in patients with systemic lupus…”
Get full text

Systemic lupus erythematosus and pregnancy: Before gestation, during and after childbirth by Reshetnyak, T. M., Kosheleva, N. M., Nasonov, E. L.

“…Systemic lupus erythematosus (SLE) is a disease of women of reproductive age. Up to a certain time, pregnancy was contraindicated in patients with SLE,…”
Get full text

Thrombosis risk factors in ANCA-associated vasculitis by Kharlamova, E. N., Reshetnyak, T. M., Tarasova, G. M.

“…The article presents a review of current data on arteriovenous thrombosis risk factors in antineutrophil cytoplasmic antibody-associated vasculitis (AAV)…”
Get full text

Efficacy and safety of long-term use of low molecular weight heparins in patients with systemic lupus erythematosus and antiphospholipid syndrome by Seredavkina, N. V., Cheldieva, F. A., Shumilova, A. A., Reshetnyak, T. M.

“…   To date, the management of patients with antiphospholipid syndrome (APS) with ineffectiveness and/or intolerance to vitamin K antagonists and direct oral…”
Get full text

Skin lesions in systemic lupus erythematosus. Part 2: clinical and histological features by Shumilova, A. A., Travkina, E. I., Reshetnyak, T. M.

“…Skin lesions in systemic lupus erythematosus (SLE) are not just a cosmetic defect, accompanied by a deterioration in the quality of life and psychological…”
Get full text

Citrullinated histone H3 in systemic lupus erythematosus and antiphospholipid syndrome (preliminary results) by Nurbaeva, K. S., Reshetnyak, T. M., Cherkasova, M. V., Lila, A. M.

“…Citrullinated histone H3 (CitH3) is a specific marker for NETosis; its role in determining the clinical and laboratory manifestations of systemic lupus…”
Get full text

Skin lesions in systemic lupus erythematosus. Part 1: classification, etiology, pathogenesis by Shumilova, A. A., Travkina, E. I., Reshetnyak, T. M.

“…Skin and mucous membranes lesions in systemic lupus erythematosus (SLE) significantly impair the quality of life of patients, although they are not a…”
Get full text

Vaccination of pneumococcal infection in patients with systemic lupus erythe matosus and antiphospholipid syndrome: experience of 6 years of use by Tarasova, G. M., Belov, B. S., Reshetnyak, T. M., Cherkasova, M. V.

“…Infections remain one of the main causes of morbidity and mortality in patients with immuno-inflammatory rheumatic diseases. Objective – to study the efficacy,…”
Get full text

Pregnancy and its outcome in antiphospholipid syndrome after acute cerebral circulatory failure (clinical case study) by Reshetnyak, T. M., Cheldieva, F. A., Kosheleva, N. M., Shumilova, A. A., Blank, L. M., Seredavkina, N. V.

“…Obstetric pathology (pregnancy loss at different gestational ages; premature delivery of morphologically normal foetus due to pre-/eclampsia or placental…”
Get full text

Direct-acting oral anticoagulants in antiphospholipid syndrome by Reshetnyak, T. M., Nurbaeva, K. S.

“…Antiphospholipid syndrome is an acquired autoimmune thrombophilia characterized by the development of recurrent vascular thrombosis of any caliber and type or…”
Get full text

Inflammatory and neutrophil activation markers in Behcet's disease by Nurbaeva, K. S., Reshetnyak, T. M., Goloeva, R. G., Lila, A. M., Nasonov, E. L.

“…Behcet's disease (BD) is a systemic vasculitis characterized by recurrent episodes of inflammation with aphthous stomatitis, genital ulcers, skin, joint and…”
Get full text